Cargando…
Efficacy of lutein supplements on macular pigment optical density in highly myopic individuals: A randomized controlled trial
Lutein supplementation is beneficial in preventing maculae from developing serious ocular diseases. This study aimed to evaluate the efficacy and safety of lutein administration in patients with high myopia (HM). METHODS: In a single-center randomized double-blinded placebo-controlled trial conducte...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036027/ https://www.ncbi.nlm.nih.gov/pubmed/36961139 http://dx.doi.org/10.1097/MD.0000000000033280 |
_version_ | 1784911551682052096 |
---|---|
author | Yoshida, Takeshi Takagi, Yasutaka Igarashi-Yokoi, Tae Ohno-Matsui, Kyoko |
author_facet | Yoshida, Takeshi Takagi, Yasutaka Igarashi-Yokoi, Tae Ohno-Matsui, Kyoko |
author_sort | Yoshida, Takeshi |
collection | PubMed |
description | Lutein supplementation is beneficial in preventing maculae from developing serious ocular diseases. This study aimed to evaluate the efficacy and safety of lutein administration in patients with high myopia (HM). METHODS: In a single-center randomized double-blinded placebo-controlled trial conducted over 24 months, 22 eyes were enrolled in lutein and control groups. Among them, 15 eyes in the lutein group and 13 eyes in the control group completed the study. All patients with HM (axial length > 26.00) were administered lutein (20 mg) or placebo once daily for 6 months. The macular pigment optical density (MPOD), rate of change in MPOD, visual acuity, contrast sensitivity, and electroretinogram after administration were examined at baseline, 3 months, and 6 months. RESULTS: The baseline MPOD in the control and lutein groups was 0.71 ± 0.21 and 0.70 ± 0.22, respectively. The MPOD in the control and lutein groups at 3 months was 0.70 ± 0.21 and 0.70 ± 0.25, respectively, and at 6 months was 0.66 ± 0.20 and 0.72 ± 0.27, respectively, which was not significantly different from those at baseline or between the groups. The MPOD significantly increased from baseline in the lutein group with less than 28.25 mm of axial length at 6 months (from 0.71 ± 0.20 to 0.78 ± 0.22, P = .02, t test). visual acuity, contrast sensitivity, and electroretinogram values were similar between the groups. CONCLUSION: Lutein supplementation showed significant benefits in MPOD augmentation in patients with HM. |
format | Online Article Text |
id | pubmed-10036027 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-100360272023-03-24 Efficacy of lutein supplements on macular pigment optical density in highly myopic individuals: A randomized controlled trial Yoshida, Takeshi Takagi, Yasutaka Igarashi-Yokoi, Tae Ohno-Matsui, Kyoko Medicine (Baltimore) 5800 Lutein supplementation is beneficial in preventing maculae from developing serious ocular diseases. This study aimed to evaluate the efficacy and safety of lutein administration in patients with high myopia (HM). METHODS: In a single-center randomized double-blinded placebo-controlled trial conducted over 24 months, 22 eyes were enrolled in lutein and control groups. Among them, 15 eyes in the lutein group and 13 eyes in the control group completed the study. All patients with HM (axial length > 26.00) were administered lutein (20 mg) or placebo once daily for 6 months. The macular pigment optical density (MPOD), rate of change in MPOD, visual acuity, contrast sensitivity, and electroretinogram after administration were examined at baseline, 3 months, and 6 months. RESULTS: The baseline MPOD in the control and lutein groups was 0.71 ± 0.21 and 0.70 ± 0.22, respectively. The MPOD in the control and lutein groups at 3 months was 0.70 ± 0.21 and 0.70 ± 0.25, respectively, and at 6 months was 0.66 ± 0.20 and 0.72 ± 0.27, respectively, which was not significantly different from those at baseline or between the groups. The MPOD significantly increased from baseline in the lutein group with less than 28.25 mm of axial length at 6 months (from 0.71 ± 0.20 to 0.78 ± 0.22, P = .02, t test). visual acuity, contrast sensitivity, and electroretinogram values were similar between the groups. CONCLUSION: Lutein supplementation showed significant benefits in MPOD augmentation in patients with HM. Lippincott Williams & Wilkins 2023-03-24 /pmc/articles/PMC10036027/ /pubmed/36961139 http://dx.doi.org/10.1097/MD.0000000000033280 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | 5800 Yoshida, Takeshi Takagi, Yasutaka Igarashi-Yokoi, Tae Ohno-Matsui, Kyoko Efficacy of lutein supplements on macular pigment optical density in highly myopic individuals: A randomized controlled trial |
title | Efficacy of lutein supplements on macular pigment optical density in highly myopic individuals: A randomized controlled trial |
title_full | Efficacy of lutein supplements on macular pigment optical density in highly myopic individuals: A randomized controlled trial |
title_fullStr | Efficacy of lutein supplements on macular pigment optical density in highly myopic individuals: A randomized controlled trial |
title_full_unstemmed | Efficacy of lutein supplements on macular pigment optical density in highly myopic individuals: A randomized controlled trial |
title_short | Efficacy of lutein supplements on macular pigment optical density in highly myopic individuals: A randomized controlled trial |
title_sort | efficacy of lutein supplements on macular pigment optical density in highly myopic individuals: a randomized controlled trial |
topic | 5800 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036027/ https://www.ncbi.nlm.nih.gov/pubmed/36961139 http://dx.doi.org/10.1097/MD.0000000000033280 |
work_keys_str_mv | AT yoshidatakeshi efficacyofluteinsupplementsonmacularpigmentopticaldensityinhighlymyopicindividualsarandomizedcontrolledtrial AT takagiyasutaka efficacyofluteinsupplementsonmacularpigmentopticaldensityinhighlymyopicindividualsarandomizedcontrolledtrial AT igarashiyokoitae efficacyofluteinsupplementsonmacularpigmentopticaldensityinhighlymyopicindividualsarandomizedcontrolledtrial AT ohnomatsuikyoko efficacyofluteinsupplementsonmacularpigmentopticaldensityinhighlymyopicindividualsarandomizedcontrolledtrial |